Literature DB >> 2328560

Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function.

W S Cheng1, T L Murphy, M T Smith, W G Cooksley, J W Halliday, L W Powell.   

Abstract

Caffeine clearance was determined in 13 healthy control subjects and in 13 patients with histologically proven cirrhosis. On separate occasions, 70 mg, 200 mg, and 300 mg single doses of anhydrous caffeine were administered orally with decaffeinated coffee to each subject. Subjects were analyzed individually, acting as their own controls, thus reducing interindividual variability. The present study showed that caffeine exhibited dose-dependent pharmacokinetics, particularly in subjects who showed high initial clearance with the low dose (70 mg) of caffeine. There was a significant decrease in caffeine clearance with increasing dose from 70 mg to 300 mg (n = 26, p less than 0.01, Dunnett's test), indicating saturable caffeine metabolism in the dose range tested. These findings imply that if caffeine is to be used as a guide to deteriorating liver function, serial caffeine clearance estimations should be performed in each individual subject, with use of the same dose of caffeine each time.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328560     DOI: 10.1038/clpt.1990.66

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  Caffeine and endurance performance.

Authors:  M A Tarnopolsky
Journal:  Sports Med       Date:  1994-08       Impact factor: 11.136

2.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

3.  Life-threatening hypokalaemia and lactate accumulation after autointoxication with Stacker 2, a 'powerful slimming agent'.

Authors:  L R H de Wijkerslooth; B C P Koch; M M Malingré; P Smits; A K M Bartelink
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

Review 4.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

5.  Caffeine does not significantly reduce the sensitivity of vasodilator stress MPI: Rebuttal.

Authors:  Eliana Reyes
Journal:  J Nucl Cardiol       Date:  2016-02-10       Impact factor: 5.952

6.  A Randomized, Two-Way Crossover Study to Evaluate the Pharmacokinetics of Caffeine Delivered Using Caffeinated Chewing Gum Versus a Marketed Caffeinated Beverage in Healthy Adult Volunteers.

Authors:  Paul Sadek; Xiao Pan; Phil Shepherd; Elise Malandain; John Carney; Hugh Coleman
Journal:  J Caffeine Res       Date:  2017-12-01

7.  Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples.

Authors:  A Nordmark; S Lundgren; S Cnattingius; A Rane
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

8.  Influence of age, frailty and liver function on the pharmacokinetics of brofaromine.

Authors:  J Zeeh; L Fuchs; W Bergmann; K H Antonin; F Degel; P Bieck; D Platt
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

9.  Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.

Authors:  Tashinga E Bapiro; Jane Sayi; Julia A Hasler; Mary Jande; Gerald Rimoy; Amos Masselle; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2005-10-29       Impact factor: 2.953

10.  Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects.

Authors:  C Csajka; C A Haller; N L Benowitz; D Verotta
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.